RxDoctor Payments Data

Lisa Banchik, MD

Neurology · Boca Raton, FLNPI 1699705863

Payments from drug & device makers

$20,719in general payments, 2019–2025

Across 628 payments — averaging $32.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$7K
  • AbbVie$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Scilex Pharmaceuticals Inc.$753
  • Pfizer$751
  • Collegium Pharmaceutical, Inc.$725
  • plus $8K from 53 others

What the payments were for

  • Consulting fees$4,77923%
  • Travel & lodging$1,8509%
  • Food & beverage$14,05968%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis20$6,858
AbbVie(2 entities)96$2,446
Biohaven Pharmaceuticals, Inc.53$1,009
Scilex Pharmaceuticals Inc.38$753
Pfizer34$751
Collegium Pharmaceutical, Inc.42$725
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC45$712
Teva Pharmaceuticals USA, Inc.18$575
Upsher-smith Laboratories LLC27$439
Idorsia Pharmaceuticals US Inc8$413
Supernus Pharmaceuticals, Inc.35$412
Neurelis, Inc.11$381
Acadia Pharmaceuticals Inc4$373
Eli Lilly1$350
Biohaven Pharmaceutical Holding Company Ltd.24$340
Lilly USA, LLC13$321
Otsuka America Pharmaceutical, Inc.4$281
Takeda Pharmaceuticals U.S.A., Inc.17$256
Axsome Therapeutics, Inc.8$253
Avanir Pharmaceuticals, Inc.19$217
Jazz Pharmaceuticals Inc.7$199
Harmony Biosciences LLC14$198
Daiichi Sankyo Inc.11$179
Amgen(2 entities)8$167
Merck9$163
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$160
UCB, Inc.2$150
AstraZeneca(2 entities)4$149
Livanova USA, Inc.1$142
C2n Diagnostics, LLC2$134
SK Life Science, Inc.1$125
E.r. Squibb & Sons, L.L.C.1$120
Eisai Inc.4$94
Lundbeck LLC3$82
Biodelivery Sciences International, Inc.5$80
Insightec,inc3$74
Biogen3$53
Neurocrine Biosciences, Inc.3$51
Valinor Pharma, LLC2$38
Cumberland Pharmaceuticals, Inc.2$37
Amneal Pharmaceuticals LLC2$35
Inspire Medical Systems, Inc.1$33
Promius Pharma LLC2$32
Immedica Pharma US, Inc.1$30
Tanabe Pharma America, Inc.1$30
Springworks Therapeutics, Inc.1$29
Assertio Therapeutics, Inc.2$27
Aucta Pharmaceuticals, Inc.1$27
EMD Serono, Inc.1$26
Johnson & Johnson1$24
Boston Scientific1$22
Shire North American Group Inc1$22
Indivior Inc.1$21
Redhill Biopharma Inc.1$20
Kvk-tech, Inc.2$19
Impel Pharmaceuticals Inc.1$18
OWP Pharmaceuticals, Inc.1$17
Ironshore Pharmaceuticals Inc.1$14
Hikma Pharmaceuticals USA1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,719 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$219,476
Medicare patients
149
Services billed
1,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate189$209,050
OxycontinOxycodone Hcl180$167,770
Nurtec OdtRimegepant Sulfate61$114,927
UbrelvyUbrogepant54$88,280
RelistorMethylnaltrexone Bromide25$64,268
PercocetOxycodone Hcl/Acetaminophen12$52,897
LinzessLinaclotide27$23,723
VraylarCariprazine Hcl12$19,577
MovantikNaloxegol Oxalate43$18,250
QuliptaAtogepant12$16,626
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen311$16,132
Oxycodone Hcl503$13,524
Morphine Sulfate ErMorphine Sulfate305$13,274
ZtlidoLidocaine18$12,593
Fentanyl102$12,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$725$209,050189 claims
AbbVieUbrelvy, Linzess, Vraylar, Qulipta$2,446$148,206105 claims
PfizerNurtec Odt$751$114,92761 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$712$64,26825 claims
Redhill Biopharma Inc.Movantik$20$18,25043 claims
Hikma Pharmaceuticals USAMorphine Sulfate, Buprenorphine, Buprenorphine-Naloxone$13$14,924177 claims
Scilex Pharmaceuticals Inc.Ztlido$753$12,59318 claims
MerckBelsomra$163$9,96123 claims
Upsher-smith Laboratories LLCTopiramate$439$1,245154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →